ImmunityBio (NASDAQ:IBRX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report published on Friday morning,Benzinga reports. D. Boral Capital currently has a $30.00 target price on the stock.

Other equities analysts have also issued research reports about the company. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. BTIG Research initiated coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 target price on the stock.

ImmunityBio Stock Performance

Shares of ImmunityBio stock opened at $3.62 on Friday. ImmunityBio has a 12 month low of $2.28 and a 12 month high of $10.53. The stock’s fifty day moving average price is $3.00 and its 200-day moving average price is $3.83.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stephens Inc. AR acquired a new stake in ImmunityBio in the fourth quarter worth about $26,000. Cibc World Markets Corp acquired a new stake in ImmunityBio in the fourth quarter worth about $35,000. Maia Wealth LLC acquired a new stake in ImmunityBio in the fourth quarter worth about $37,000. Schechter Investment Advisors LLC acquired a new stake in ImmunityBio in the fourth quarter worth about $38,000. Finally, Captrust Financial Advisors acquired a new stake in shares of ImmunityBio during the third quarter worth about $41,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.